Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial
Research output: Contribution to journal › Article › peer-review
20Citations
(Scopus)
106Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial'. Together they form a unique fingerprint.